24-Hour Crisis Hotline: (877)SAFEGBC or (877)723-3422 Mental Health & Substance Abuse Issues

6502 Nursery Drive, Suite 100
Victoria, TX 77904
(361)575-0611
(800)421-8825
Fax: (361)578-5500

Medical Disorders
Resources
Basic InformationLookupsLatest News
AHA News: High Blood Pressure Common Among Black Young AdultsAHA News: Congenital Heart Disease Linked to Neighborhood Pollution, PovertySome Headway Made Against 'Superbugs,' but Threat Remains: CDCHealth Tip: A Well-Stocked First-Aid KitLung Cancer Report Delivers Good, Bad NewsAHA News: Millions Unaware of Common Heart Attack SymptomsWant Extra Years of Life? Keep Blood Pressure Tightly ControlledTestosterone Supplements Double Men's Odds for Blood Clots: StudyHealth Tip: Treating Post-Nasal DripOpioids Won't Help Arthritis Patients Long-Term: StudyCommon Muscle Relaxant Could Pose Mental Dangers for SeniorsKratom May Cause Liver Damage: StudySupplements Don't Prevent Kidney Disease in Type 2 DiabeticsNew Tool Predicts Odds of Kidney DiseaseVitamin E Acetate Is Leading Suspect in Vaping-Linked Lung Illnesses: CDCVaping-Linked Lung Illnesses Top 2,000, CDC SaysAHA News: Stroke Death Rate Increasing for Middle-Aged AmericansRural Americans Dying More From Preventable Causes Than City DwellersWhy Hand-Washing Beats Hand SanitizersSleepless Nights Could Raise Heart RisksScreening Truckers for Sleep Apnea Cuts Health Insurance CostsDo You Take Biotin Supplements? They Could Affect Your Medical TestsAHA News: Heart Disease Down Over A Generation Among American IndiansRisks Mount for Lonely Hearts After Cardiac SurgeryDaylight Saving Time Bad for Health, Experts ClaimHealth Tip: Prevent BloatingCould a Blood Test for Breast Cancer Become a Reality?One Dead, 8 Hospitalized in Salmonella Outbreak Tied to Ground BeefMost Americans Fear Cancer, but Feel Powerless to Prevent It: SurveyFewer Opioids After Eye Surgery Don't Mean More Post-Op PainDrug Trio Could Give Patients With Cystic Fibrosis a New OptionCould Tissue-Sealing Tape One Day Replace Stitches?Deep Sleep May 'Rinse' Day's Toxins From BrainClose to 1,900 Cases of Vaping-Linked Lung Illness, CDC SaysMeasles Leaves People More Vulnerable to Future InfectionsHealth Tip: Nausea After EatingSooner Is Usually Better for Gallbladder SurgeryProtect Your Heart Through the Holiday SeasonReport Finds Americans' Health Is FlaggingAHA News: Retina Changes Offer Glimpse Into Body's Heart HealthWildfire Smoke Threatens Health for Miles AroundHealth Tip: Hand Swelling During ExerciseToo Many Seniors Back in Hospital for Infections Treated During First StayHealth Tip: Cold, Flu or Allergy?Health Tip: What Your Urine Color May MeanNew Database Shows 'Rare' Diseases Are Not So Rare WorldwideIs Head Injury Causing Dementia? MRI Might ShowAHA News: How Does Hormone Therapy Affect Heart Health in Transgender People?Antihistamines Linked to Delayed Care for Severe Allergic Reaction: StudyCould More Coffee Bring a Healthier Microbiome?
Questions and AnswersLinks
Related Topics

Diabetes

Pretomanid Approved for Treatment of Drug-Resistant TB


HealthDay News
Updated: Aug 14th 2019

new article illustration

WEDNESDAY, Aug. 14, 2019 (HealthDay News) -- Pretomanid tablets in combination with bedaquiline and linezolid have been approved for the treatment of a highly treatment-resistant type of pulmonary tuberculosis (TB), the U.S. Food and Drug Administration announced today.

The treatment combination was approved to treat adult patients with extensively drug-resistant, treatment-intolerant, or nonresponsive multidrug-resistant pulmonary TB. Dosing involves 200 mg of Pretomanid tablets orally once daily for 26 weeks, 400 mg of bedaquiline orally once daily for two weeks followed by 200 mg three times per week for 24 weeks, and 1,200 mg of oral linezolid daily for up to 26 weeks.

Researchers evaluated the safety and effectiveness of Pretomanid taken in combination with bedaquiline and linezolid in a study of 107 patients with extensively drug-resistant, treatment-intolerant, or nonresponsive multidrug-resistant pulmonary TB. At six months posttherapy, 89 percent of patients were successfully treated, which according to the FDA, exceeds the historical success rates for extensively drug-resistant TB. The most commonly reported adverse reactions included peripheral neuropathy, acne, anemia, nausea, vomiting, headache, elevated transaminases and gamma-glutamyltransferase, dyspepsia, rash, hyperamylasemia, visual impairment, hypoglycemia, and diarrhea.

The drug combination of Pretomanid and bedaquiline and linezolid should not be used in patients with hypersensitivity to bedaquiline or linezolid or those with drug-resistant tuberculosis, latent infection or extrapulmonary infection due to Mycobacterium tuberculosis, or multidrug TB that is not treatment-intolerant or nonresponsive to standard therapy.

Approval was granted to The Global Alliance for TB Drug Development.

More Information